Joint injury can result in a profound imbalance in cartilage catabolic and anabolic processes culminating in degenerative osteoarthritis. Interleukin-1 is regarded as the principal cartilagedegradative cytokine in OA, and has an important role in other joint diseases including rheumatoid arthritis. Reducing the impact of IL-1 has been possible using IL-1 receptor antagonist. However, the transitory nature of IL-1Ra requires daily re-dosing, leading to development of gene therapy approaches to extend the proinflammatory cytokine control.
INTRODUCTION
Joint injury can result in a profound imbalance in cartilage catabolic and anabolic processes culminating in degenerative osteoarthritis. Interleukin-1 is regarded as the principal cartilagedegradative cytokine in OA, and has an important role in other joint diseases including rheumatoid arthritis. Reducing the impact of IL-1 has been possible using IL-1 receptor antagonist. However, the transitory nature of IL-1Ra requires daily re-dosing, leading to development of gene therapy approaches to extend the proinflammatory cytokine control.
1,2 A direct IL-1 transcript silencing approach rather than receptor antagonism has been evaluated using small interfering RNA (siRNA) ribo-oligonucleotides targeting IL-1 mRNA.
3 To be effective in vivo, plasmid based IL-1 silencing is necessary to overcome the transitory nature of oligo based knockdown. The hypothesis for this study was that IL-1 expression could be better controlled using short hairpin plasmid and ultimately integrating transposon plasmid based gene silencing motifs targeting IL-1.
METHODS
Five small interfering RNA's (siRNA) for IL-1β were chemically generated (Ambion). Chondrocytes cultured in medium containing lipopolysaccharide (LPS) at 25 μg/mL, to induce IL-1β gene expression, were electroporated with siRNA using a BTX ECM 830 electroporator (Harvard Instruments). After electroporation, cells were plated with 25 μg/mL LPS for another 24 hours. RNA was isolated and real time PCR gene expression analysis performed. The most effective siRNA ribo-oligonucleotide was used as the template to form pSH.IL-1β, a plasmid based short hair-pin coding construct based on the pSIREN shuttle plasmid (Clontech). Following LPS treatment, cells were electroporated with 4ug pSH.IL-1β. IL-1b expression was assessed at 24 hrs postelectroporation. Subsequently, the pSH.IL-1β expression cassette was recombined into the Sleeping Beauty (SB) transposon plasmid upstream of a bicistronic expression/selection cassette derived from pIRESpuro3 (Clontech). Cells were electroporated with an equimolar mix of SB-sh.IL1b and the SB transposase-carrying pCMV-SB plasmid. Ten days post selection (puromycin), genomic integration was confirmed by PCR of genomic DNA for the SBsh.IL1b construct. IL1b expression was assessed in SB-sh.IL1b cells and wild-type cells following 48 hr LPS treatment as described above. Data were analyzed using ANOVA with post-hoc Tukeys classifications. RESULTS Six small interfering RNA's (siRNA) targeting IL-1β were screened by electroporation into chondrocyte monolayers exposed to LPS. Gene expression for IL-1β and MMP-13 were returned to baseline by several IL-1 silencing ribo-oligonucleotides. Effective siRNA ribo-oligo's were constructed as plasmid based short hairpin coding constructs to prolong IL-1 knockdown (pSIREN-IL1shRNA). IL-1 shRNA loops, with or without IGF-I gene transduction (bicistronic plasmid expressing IGF-I and IL-1β shRNA), prolonged matrix restorative effects. Chondrocyte monolayers expressing IL-1 shRNA had >60% reduction in IL-1 abundance (Fig  1) .
Medium from IL-1 shRNA knockdown trials showed consistent IL-1 reduction after shRNA transduction.
Effective IL-1 shRNA and IGF-1 coding motifs were developed into Sleeping Beauty plasmid based vectors for transduction of chondrocyte and synoviocyte cultures. Both transgenes were expressed and IL-1 shRNA suppressed IL-1 fluxes in LPS conditioned cultures (Fig 3) .
DISCUSSION:
These data show novel IL-1 knockdown using a plasmid coding a short hairpin loop (shRNA) form of an IL-1 interference motif. This plasmid allowed stable expression of siRNA following intracellular Dicer activity. Moreover, development of this plasmid by recombination into the Sleeping Beauty (SB) transposon, provided potential for chromosomal integration and selection of chondrocytes resistant to IL-1 effects. Target gene knockdown provides a non-competitive path to control IL-1 action, compared to previous IL-1 receptor antagonism, where the need for molar excess of IL-1Ra over IL-1 was paramount. Similarly, posttranscriptional gene silencing has the advantage of persistence, particularly when combined with integrating vectors such as SB. Implementation of integrating mechanisms may be useful for substantial control of degradation and improved function in OA joints. Adding IGF-I to the combinatorial approach to drive further repair in the face of diminished catabolic erosion may further improve the possibility effective OA control. 
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